title: Management of pain, agitation, and delirium in critically ill patients.
abstract: Pain, agitation, and delirium (PAD) are common in critically ill patients. Consequently, analgesic and sedative medications are frequently administered to critically ill patients to treat PAD, to improve synchrony with mechanical ventilation, and to decrease the physiological stress response. However, prolonged, continuous deep sedation of intensive care unit (ICU) patients is associated with numerous adverse outcomes, including longer durations of mechanical ventilation, prolonged ICU stays, acute brain dysfunction, and an increased risk of death. The 2013 ICU PAD Guidelines were developed to provide a clear, evidence-based road map for clinicians to better manage PAD in critically ill patients. Significant knowledge gaps in these areas still remain, but if widely adopted, the PAD Guidelines can help bridge these gaps and will be transformative in terms of their impact on ICU care. Strong evidence indicates that linking PAD management strategies with ventilator weaning, early mobility, and sleep hygiene in ICU patients will result in significant synergistic benefits to patient care and reductions in costs. An interdisciplinary team-based approach, using proven process improvement strategies, and ICU patient and family activation and engagement, will help ensure successful implementation of the ICU PAD Care Bundle in ICUs. This paper highlights the major recommendations of the 2013 ICU PAD Guidelines. We hope this review will help ICU physicians and other health care providers advance the management of PAD in critically ill patients, and improve patients' clinical outcomes.
authors.forename: Pratik P
authors.initials: PP
authors.lastname: Pandharipande
authors.forename: Mayur B
authors.initials: MB
authors.lastname: Patel
authors.forename: Juliana
authors.initials: J
authors.lastname: Barr
mesh_terms: D000700:Analgesics / Q000627:therapeutic use; D003422:Critical Care / Q000592:standards; D016638:Critical Illness / Q000523:psychology* / Q000628:therapy*; D003693:Delirium / Q000209:etiology / Q000517:prevention & control*; D019317:Evidence-Based Medicine; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D007902:Length of Stay; D010146:Pain / Q000209:etiology / Q000517:prevention & control*; D059408:Pain Management / Q000379:methods* / Q000592:standards*; D017410:Practice Guidelines as Topic; D011595:Psychomotor Agitation / Q000209:etiology / Q000517:prevention & control*; D012121:Respiration, Artificial / Q000592:standards
chemical_list: D000700:Analgesics; D006993:Hypnotics and Sedatives